Dr. Jean Wactawski-Wende, professor in the department of epidemiology and environmental health, at the University of Buffalo SUNY School of Public Health and Health Professions, is a principal investigator of the Buffalo EAGeR trial and co-author of the study, “Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomized trial”. It is published in the current issue of The Lancet. The Effects of Aspirin in Gestation and Reproduction (EAGeR) medical trial has found that, in general, low-dose aspirin is not beneficial for future pregnancy outcomes in women with prior pregnancy loss. However, in women with one pregnancy loss within the previous 12 months, there did appear to be a benefit. “Women should talk to their health care providers before considering low-dose aspirin or any other medication while attempting to get pregnant or during pregnancy. But based on this trial, general use of low-dose aspirin is not recommended,” says Dr. Wactawski-Wende.